NCT07545993

Brief Summary

Necrotizing enterocolitis (NEC) is one of the most severe gastrointestinal emergencies in preterm infants, characterized by insidious onset, rapid progression, and high mortality. It can lead to serious adverse outcomes such as intestinal perforation, short bowel syndrome, and neurodevelopmental disorders, making it a critical condition that significantly impacts the survival quality and long-term prognosis of preterm infants.With the advancement of perinatal medicine in China, the survival rates of extremely low and very low birth weight infants have been continuously improving. NEC has become a critical bottleneck constraining the quality of care and long-term prognosis for preterm infants. Previous studies have demonstrated that various perinatal and early postnatal factors, including gestational age, birth weight, infection, feeding methods, blood transfusion, mechanical ventilation, and antibiotic exposure, are associated with the occurrence of NEC. However, these clinical factors still fail to adequately explain the interindividual variations in NEC incidence risk and disease severity under similar clinical exposure conditions.Existing NEC prediction models primarily rely on static baseline variables for one-time risk assessment, lacking dynamic risk updates during hospitalization, and most are derived from single-center retrospective studies. With the application of clinical exome sequencing (CES), the role of genetic factors in susceptibility to NEC has gradually attracted attention.The research team has previously conducted NEC risk gene screening based on CES, genetic burden analysis, and exploration of genetic-clinical factor interactions, suggesting that genetic information can provide important supplementation for NEC risk assessment.Meanwhile, dynamic changes in immune-inflammatory markers such as peripheral blood eosinophils, NLR, absolute neutrophil count, and platelet count may already exhibit abnormalities prior to the onset of NEC, providing repeatable, low-cost, and clinically available signals for early identification.Based on this, this study aims to establish a multidimensional dynamic early warning system for NEC integrating single-center preliminary genetic research foundations with multi-center retrospective/prospective validation resources. This initiative seeks to enhance the identification capability of high-risk individuals and provide evidence for subsequent precision prevention and control as well as stratified management.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,050

participants targeted

Target at P75+ for all trials

Timeline
44mo left

Started Apr 2026

Typical duration for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress2%
Apr 2026Dec 2029

First Submitted

Initial submission to the registry

April 15, 2026

Completed
Same day until next milestone

Study Start

First participant enrolled

April 15, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 22, 2026

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2029

Last Updated

April 22, 2026

Status Verified

April 1, 2026

Enrollment Period

3.7 years

First QC Date

April 15, 2026

Last Update Submit

April 15, 2026

Conditions

Keywords

pretermneonateearly warning system

Outcome Measures

Primary Outcomes (1)

  • Bell stage II or higher NEC

    From April 2026 to April 2029

Study Arms (1)

VPI

very preterm infants born \<32 weeks

Other: No Intervention: Observational Cohort

Interventions

No intervention required.

VPI

Eligibility Criteria

Age0 Days - 3 Months
Sexall(Gender-based eligibility)
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Preterm infants born \<32 weeks

You may qualify if:

  • Preterm infants with gestational age \<32 weeks
  • Admission to the neonatology department of the lead institution or participating institutions
  • Parental consent to participate in the study and approval for genetic testing using residual samples from routine blood draws.
  • Possession of complete perinatal and hospitalization records.

You may not qualify if:

  • Congenital malformations, well-defined clinical syndromes, or chromosomal abnormalities
  • Death within 7 days after birth or voluntary discharge
  • Patients with confirmed positive diagnosis of pathogenic genes and interpretable major clinical phenotypes
  • Only one case of identical multiple births was retained for analysis to avoid genetic background overlap

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Enterocolitis, NecrotizingPremature Birth

Condition Hierarchy (Ancestors)

EnterocolitisGastroenteritisGastrointestinal DiseasesDigestive System DiseasesIntestinal DiseasesObstetric Labor, PrematureObstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 15, 2026

First Posted

April 22, 2026

Study Start

April 15, 2026

Primary Completion (Estimated)

December 31, 2029

Study Completion (Estimated)

December 31, 2029

Last Updated

April 22, 2026

Record last verified: 2026-04